about
Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomesPrevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproateMaternal morbidity associated with multiple repeat cesarean deliveriesInfluenza-like illness in hospitalized pregnant and postpartum women during the 2009-2010 H1N1 pandemic.Repeated courses of antenatal corticosteroids: are there effects on the infant's auditory brainstem responses?Vitamins C and E to prevent complications of pregnancy-associated hypertensionHaptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse populationPlacental villous hypermaturation is associated with idiopathic preterm birthA randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsyA multicenter, randomized trial of treatment for mild gestational diabetes.Bone metabolism in pregnant women exposed to single compared with multiple courses of corticosteroids.Timing of elective repeat cesarean delivery at term and neonatal outcomes.Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trialThe obstetric and neonatal implications of a low value on the 50-g glucose screening testRelationship between 1-hour glucose challenge test results and perinatal outcomes.Active management of labor.The effect of maternal body mass index on neonatal outcome in women receiving a single course of antenatal corticosteroids.White's classification of maternal diabetes and vaginal birth after cesarean delivery success in women undergoing a trial of labor.Bone metabolism in fetuses of pregnant women exposed to single and multiple courses of corticosteroids.Association of fetal inflammation and coagulation pathway gene polymorphisms with neurodevelopmental delay at age 2 years.Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery.Fetal male gender and the benefits of treatment of mild gestational diabetes mellitus.Maternal and neonatal outcomes of repeat cesarean delivery in women with a prior classical versus low transverse uterine incision.Maternal serum interleukin-6, C-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth <32 weeks and adverse neonatal outcomes.Vitamin C and E supplementation to prevent spontaneous preterm birth: a randomized controlled trialNeonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term.Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproateThe risk of cesarean delivery with neuraxial analgesia given early versus late in labor.Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.Admixture mapping to identify spontaneous preterm birth susceptibility loci in African Americans.Timing of elective repeat cesarean delivery at term and maternal perioperative outcomes.Maternal insulin resistance and preeclampsiaPlacental endothelial nitric oxide synthase in multiple and single dose betamethasone exposed pregnancies.Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant deathThe effect of plurality and obesity on betamethasone concentrations in women at risk for preterm deliveryMode of delivery in women with antepartum fetal death and prior cesarean delivery.Effect of antenatal corticosteroids on respiratory morbidity in singletons after late-preterm birth.Excessive early gestational weight gain and risk of gestational diabetes mellitus in nulliparous womenFirst-trimester prediction of preeclampsia in nulliparous women at low risk.
P50
Q24648089-76652D37-2844-4A84-8C7E-1B07B8CC1758Q28178563-5322A7F9-2109-46EA-8F38-FFED5E3B50F0Q28243198-B8498757-6A4B-4689-9E0E-6AA52A36023CQ30406291-9724F67A-66E4-45CC-8D3E-FB2B2C4C6075Q30473352-D5128FB0-B22F-4385-B4DB-7A18165DFFCDQ33389072-32F1F8AF-776D-46F2-A670-A27D05CE0300Q33406987-58AE48A5-1A04-4FB5-9854-724EAD0F76E8Q33566925-6686663B-4108-479C-A855-AA8E566ED1FAQ33577192-EE94DAFB-D75A-4BEF-9B96-0DD3F5520B67Q33583959-BE968D0F-9905-4122-B2D6-C5114E73ADACQ33605071-C2DED4EE-B3F9-4B73-A47F-D10C42B87E18Q33611728-06CC1C4E-C2E5-4720-BD95-4494BAF7B6E1Q33618715-64F06982-242B-4A51-B1E9-A8E3DC83423EQ33618977-9EE5CF60-30A1-46EA-BEF1-1482DC4D4FD0Q33642344-A4F64803-14B1-4CAA-9907-97AA55B346BFQ33683877-422CE81D-6745-4145-97AC-5E006E5FCF7DQ33712500-9A4A42B9-58AD-4300-BB1D-F1D08D019924Q33748754-99AFAB5E-4889-4532-80CC-10F41F76AEACQ33750564-C68932A6-D328-4FE1-839A-66215F3C0A20Q33977067-D8FEF1E9-CB74-4BCB-AF77-807BA883BF67Q33983805-5853F62E-CC2E-4CFD-B1F0-80435378BD31Q34088813-631D38AB-6FD9-4C01-B5E7-9EB22E7B165EQ34200396-272330C9-9C8C-4F14-9782-A38E35A4F233Q34291965-6BDF7659-E702-4355-B3B0-194EAB170BDCQ34330415-2FD427BD-67BD-4EAE-9E83-25C0F7C6A7CCQ34343324-080F95A8-363B-42D5-876B-B2B3667EB76AQ34392086-FA0D4A47-8479-4184-AE00-9BE3CAFAFBB5Q34395335-FD266EA0-4DEE-4014-8396-D1C68B6F8C97Q34629600-39014512-66E9-4902-9EDB-57935F8F7D39Q34925836-7A105EFD-6BC9-4886-B6C9-851E0B5EF375Q34982063-7430C97F-FB4C-41C9-8430-01C4B913858EQ35079529-ED096A33-0FFB-46E4-A2BD-09C127CEB122Q35079625-1A7B6248-F6F6-4A53-B5A7-3300CC8AC6BEQ35137631-205B8C22-6C82-4D45-A506-395CD3B53555Q35534268-DF1F0026-6E07-406D-ADBF-94A2DA38A0D6Q35546556-96BA440F-FF81-406E-A9CA-F60158A29076Q35737608-3BDB1981-F54F-4605-9620-51A4528BCC39Q35917654-F8F246ED-D517-4319-AE1F-4187CDCFD82CQ35988392-7B896D95-57EE-41C5-86F7-DA68CD6F492CQ35988764-52E734DB-ADB5-4920-8D53-A0C676D03463
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alan M Peaceman
@nl
Alan M Peaceman
@sl
Alan M. Peaceman
@en
Alan M. Peaceman
@es
type
label
Alan M Peaceman
@nl
Alan M Peaceman
@sl
Alan M. Peaceman
@en
Alan M. Peaceman
@es
prefLabel
Alan M Peaceman
@nl
Alan M Peaceman
@sl
Alan M. Peaceman
@en
Alan M. Peaceman
@es
P106
P1153
35402101600
P21
P31
P496
0000-0002-4515-4850